There were positive trading updates from companies covered here, including a couple of relative newcomers to AIM, as well as two investment managers commanding very different valuations. (Free to read)
Cambridge Cognition: major new pharma client
Cambridge Cognition (AIM: COG), which develops and markets digital solutions to assess brain health, has been awarded contracts for two clinical trials by a top 20 pharmaceutical company to assess the pro-cognitive effects of a new drug in schizophrenia. Together the contracts are worth £700,000 over two years.
This is the second pharmaceutical client to award Cambridge Cognition major contracts for cognitive assessments for schizophrenia in…
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.
